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ABSTRACT  
 
Objective. To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first 
biologic drug in a large series of patients with refractory uveitis due to Behçet's disease (BD) 
for 1-year period. 
Methods. Open-label multicenter study of IFX or ADA-treated patients with BD-uveitis 
refractory to conventional non-biologic treatment. IFX or ADA were chosen as first biologic 
treatment based on physician and patient agreement. Dosing schedule was: IFX: 3-5 mg/kg 
i.v. at 0, 2 and 6 weeks and every 4-8 weeks thereafter, and ADA: 40 mg/s.c./every other 
week without loading dose. Comparison between patients treated with IFX and patients 
treated with ADA was performed.  
Results. 177 patients (316 affected eyes) were included. IFX was used in 103 and ADA in 
74 cases. No significant differences at baseline were observed between IFX vs ADA groups 
regarding main demographic features, previous therapy and ocular severity. After one year 
of therapy, we observed an improvement in all ocular parameters in both groups. However, 
ADA therapy yielded better outcome in some parameters that in some cases yielded 
statistically significant differences: anterior chamber inflammation (78.18% in IFX-treated vs 
92.31%in ADA-treated; p=0.06), vitritis (78.95% vs 93.33%; p=0.04), retinal vasculitis (97% 
vs 95%; p=0.28), macular thickness (264.89±59.74 vs 250.62±36.85; p=0.15), best-
corrected visual acuity (0.67±0.34 vs 0.81±0.26; p=0.001), and drug retention (84.95% vs 
95.24%; p=0.042). 
Conclusion. Although IFX and ADA yields efficacy refractory BD uveitis, ADA appears to be 













This article is protected by copyright. All rights reserved. 
Behçet’s disease (BD) is a systemic vasculitis characterized by recurrent oral and/or genital 
ulcers, skin lesions and ocular involvement, although it can affect multiple organs [1, 2]. One 
of the major causes of disability of BD is uveitis. Several studies indicate that the risk of 
severe visual loss ranges from 13% to 74% within 6 to 10 years after the onset of the uveitis 
[3-6]. 
The prognosis of ocular involvement has improved over the last decades due to the use of 
conventional and biologic immunosuppressive therapies [7]. According to the “Expert panel 
recommendations for the use of anti-TNF-α drugs in patients with ocular inflammatory 
disorders”, published in 2014, anti-TNF therapy with infliximab (IFX) (good-quality evidence) 
or adalimumab (ADA) (moderate-quality evidence) may be considered as the first- or 
second-line corticosteroid-sparing therapy for patients with ophthalmic manifestations of BD, 
and IFX may be considered as the first- or second-line treatment for acute exacerbations of 
pre-existing BD [8]. 
In 2016, ADA was reported to be the only biologic drug that demonstrated efficacy in 
randomized double-blind Phase III studies in non-infectious intermediate, posterior uveitis 
and panuveitis [9-10]. Consequently, ADA was approved by the EMA and the FDA 
(http://www.ema.europa.eu) (http://www.fda.gov) in non-infectious non-anterior uveitis. 
However, underlying diseases included in the VISUAL trials were very heterogeneous. 
Furthermore, the VISUAL trials included very few cases of BD uveitis treated with ADA (12 
patients [11%] in the VISUAL I and 10 patients [9%] in the VISUAL II). Therefore, 
conclusions on the efficacy of ADA in BD were scarce. Moreover, little is known of 
differences in the outcome of BD uveitis treated with IFX or ADA. In this regard, there is only 
one single study comparing the efficacy of these two anti-TNF agents in adult patients with 
refractory non-infectious uveitis [11]. However,  this study included a  very heterogeneous 
group of patients, including unrelated entities to BD such as juvenile idiopathic arthritis, 
spondyloarthritis, or sarcoidosis. Moreover, patients with refractory uveitis due to BD only 
represented 36% of cases. Because of that, a specific comparison between IFX and ADA for 
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Taking into account all these considerations, we aimed to compare the efficacy and safety of 
IFX versus ADA as the first biologic drug in a large series of patients with refractory uveitis 
exclusively due to BD for 1-year of follow-up. 
 
PATIENTS AND METHODS 
Design, Enrollment Criteria, and Definitions 
We set up an observational, open-label multicenter study including 177 patients with 
refractory uveitis due to BD who were treated with IFX or ADA as the first biologic therapy. 
Dosing schedule was the following: IFX: 3-5 mg/kg i.v. at 0, 2 and 6 weeks and every 4-8 
weeks thereafter, and ADA: 40 mg/s.c./every other week (eow) without loading dose. 
All of BD patients had uveitis refractory to glucocorticoids and had previously received at 
least one conventional synthetic immunosuppressive drug. IFX was used in 103 cases and 
ADA in 74. Partial information on 124 patients of this series was previously reported [12]. 
Patients were followed-up at 52 Uveitis Units of referral Spanish hospitals. 
The diagnosis of BD was performed according to the proposed International Criteria for BD 
[13]. All of them fulfilled the recently proposed criteria for BD [14]. 
Since IFX is an off-label indication for uveitis, written informed consent was requested and 
obtained from all the patients. This was also requested for patients included in ADA group, 
since ADA was prescribed before the approval by the EMA and the FDA for the treatment of 
non-infectious and non-anterior uveitis. 
Malignancy or systemic infectious diseases, including hepatitis B or C infection, were 
excluded before anti-TNF onset, as previously described [12,15-21]. 
To exclude latent tuberculosis, a tuberculin skin test (PPD) and/or an interferon-γ assay 
(quantiFERON) and a chest radiograph were performed to all patients receiving biologic 
drugs, as indicated by the Spanish National Guidelines. If present, prophylaxis with isoniazid 
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Uveitis was anatomically classified according to the Standardization of Uveitis Nomenclature 
(SUN) Working Group [22].  
Remission was defined as the absence of signs of any intraocular inflammation for at least 3 
months. Intraocular inflammation was considered to be present if there was anterior or 
posterior chamber inflammation, retinal vasculitis, papilitis or cystoid macular edema (CME). 
A relapse was defined as a new flare of uveitis in a patient who was in remission [23]. 
The most frequent conventional immunosuppressive drugs and dosages given before ADA 
or IFX onset were cyclosporine A (CsA) (3-6 mg/kg/p.o./day), methotrexate (MTX) (7.5-25 
mg/s.c./week), and azathioprine (AZA) (100-150 mg/p.o./day). In accordance with the 
VISUAL I and VISUAL II trials, the maintenance dose of ADA was 40 mg/s.c./eow. However, 
VISUAL I and II trials were published after the onset of the present study and, because of 
that, patients from our series did not receive a loading dose of ADA. Standard loading dose 
of IFX, 3-5 mg/kg/i.v., was given at 0, 2, and 6 weeks and then they received a maintenance 
dose every 4 to 8 weeks. Both anti-TNF agents were administered in combination with 
conventional immunosuppressive drugs in 78 patients with IFX (76.5%) and in 52 patients 
with ADA (70.3%) or as monotherapy in the remaining cases. The conventional drugs used 
in combination with ADA and IFX are shown in Table 1. 
 
Outcome Variables 
The outcome variables were efficacy, safety and retention rate. To determine efficacy, the 
intraocular inflammation, macular thickness, visual acuity, the degree of immunosuppression 
load, the number of relapses and the sparing glucocorticoid effect were assessed. These 
outcome variables were recorded at baseline, 1 week, 2 weeks, 1 month, 3 months, 6 
months and 1 year after IFX or ADA onset. They were assessed in each center according to 
a follow-up protocol agreed beforehand. 
The degree of intraocular inflammation was evaluated according to the SUN Working Group 
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(BCVA) was estimated using the Snellen chart. Following SUN recommendations [22], 
improvement of anterior uveitis activity was defined as either a two-step decrease in the 
level of inflammation or a decrease to grade 0 in the level of inflammation (the scale is the 
following: 4, 3, 2, 1, 0.5 and 0). Inactive anterior uveitis (grade 0) was defined as <1 cell per 
field in the anterior chamber (AC) on slit lamp examination. A worsening activity was defined 
as either a two-step increases in the level of inflammation or an increase to grade 4. Similar 
definition was used for the improvement of vitritis haze. 
Fluorescein angiography (FA) was performed to assess the presence of vasculitis. FA 
results were reviewed for the presence of vasculitis, papillitis and CME. Retinal vasculitis 
was defined as a retinal angiographic leakage, staining and/or occlusion on FA [4].  
Choroiditis and retinitis were considered active or inactive depending on the presence or 
absence, respectively, of activity data on ophthalmoscopic examination and/or FA.  
High-Definition Optical Coherence Tomography (OCT) was the technique used to measure 
the macular thickness. It consists of a non-invasive imaging technique that uses light waves 
to obtain high-resolution cross-sectional images of the retina. Scans were obtained using the 
512x128 scan pattern. Macular thickening was defined as a macular thickness >250 µm, 
whereas CME was considered to be present if macular thickness was >300 µm. 
The degree of immunosuppression was calculated according to the semiquantitative scale 
proposed by Nussenblatt et al. [25, 26]. The grading scheme provides a combined, single 
numeric score for the total immunosuppression load per unit of body weight per day. Grades 
for each agent (prednisone, CsA, AZA, MTX, and other immunosuppressants) ranged on a 
scale from 0 to 9, whereas mycophenolate mofetil ranged from 0 to 7. For patients receiving 
multiple medications, the sum of the grading score for each drug was used to calculate the 
total immunosuppression score at the baseline visit and at each visit on a scale from 0 to 15. 
Topical or periocular corticosteroid therapy was excluded from the calculation of the 
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Statistical Analysis 
Results were expressed as mean ± standard deviation (SD) for variables with a normal 
distribution, or as median and interquartile range [25th-75th interquartile range (IQR)] for 
those not normally distributed. Continuous variables (normally and not normally distributed) 
were compared with the 2-tailed Student t test or the Mann Whitney U test, respectively. The 
chi-square test or the Fisher exact test was used for the dichotomous variables. The 
Wilcoxon signed-rank test was used to compare continuous variables between the two 
groups of treatment. The following variables were assessed and compared between 
baseline (first visit before anti-TNFα onset), 1 week, 2 weeks, 1 month, 3 months, 6 months 
and 1 year separately in each group: BCVA, AC cells, vitritis, retinal vasculitis, and OCT. 
Besides, mixed linear models are used with repeated measures data to accommodate the 
effects of treatment and time and the covariation between observations on the same subject 
at different times. This mixed model allows a greater flexibility in modeling covariance 
structures for repeated measures data, and adequately accounts for the within-subject time-
dependent correlations. Further, the Bonferroni test for multiple comparisons was performed 
in order to control for the familywise error rate. Statistical significance was considered as a 
p-value<0.05. Statistical analysis was performed by using the STATISTICA software 
(StatSoft, Tulsa, OK, USA). 
 
RESULTS  
Baseline demographic and clinical features in both ADA and IFX groups 
A total of 177 patients (316 affected eyes) with uveitis refractory to conventional 
immunosuppressive therapy were studied (Table 1). 103 patients (58%) were treated with 
IFX and 74 patients (42%) with ADA as the first biologic agent. In both groups, men slightly 
outnumbered women (55 men/48 women in the IFX group and 39 men/35 women in ADA 
group; p=0.93). The mean age was similar in both groups (40.4±10.1 years in the IFX group 
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patients in both groups (69.4% vs 68.9%; p=0.74). In most cases uveitis was bilateral 
(79.61% in IFX group vs 77.03% in ADA group; p=0.68).  
Regarding previous therapy, there were not statistically significant differences in the 
administration of oral glucocorticoids between both groups (95% in IFX group vs 88% in 
ADA group; p=0.08; mean maximum prednisone daily dosage 54.35±15.84 mg/day in IFX 
group vs 53.37±17.52 in ADA group; p=0.37), intravenous pulses of 6-methylprednisolone 
(MP) (31% in both groups; p=0.98). It was also the case for the percentage of patients 
treated with CsA, MTX, and cyclophosphamide (Table 1). However, we found a significantly 
higher percentage of patients receiving AZA before the onset of IFX (57%) compared with 
that of the ADA group (42%; p=0.049). Also, no significant differences were observed in the 
dose of the different conventional immunosuppressive drugs in the IFX and ADA groups: 
CsA (mean dose: 4.9±0.8 mg/kg/day vs 4.8±0.8 mg/kg/day; p=0.88), MTX (mean dose: 
15.6±4.6 mg/week vs 16.7±3.6 mg/week; p=0.17), and AZA (mean dose 137.2±32.3 mg/day 
vs 127.4±25.3 mg/day; p=0.14). Moreover, the immunosuppression load score was similar in 
both groups (mean 9.07± 4.14 vs 8.01±5.24; p= 0.2). 
The median period between the onset of uveitis and the beginning of the anti-TNF therapy 
was also similar in both groups (median [IQR]; 36 months [12-72] vs 48 months [12-60]; 
p=0.69). 
 
Visual outcome, glucocorticoid-sparing effect and immunosuppression load score at 
one year of ADA and IFX therapy  
The standard loading dose of IFX (3-5 mg/kg i.v.) was given at 0, 2 and 6 weeks and then 
the patients received a maintenance dose every 4-8 week. The IFX onset regimen was as 
follows: 3 mg/kg i.v. and maintenance dose every 4 weeks (1 case), every 6 weeks (2 cases) 
and every 8 weeks (5 cases); 4 mg/kg i.v. and maintenance dose every 4 weeks (1 case); 5 
mg/kg i.v. and maintenance dose every 4 weeks (15 cases), every 6 weeks (18 cases), 
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During the first year of treatment, we observed an improvement in all ocular parameters in 
both IFX and ADA groups.  Nevertheless, improvement in some parameters yielded 
statistically significant differences in favor of ADA therapy: AC inflammation (78.18% with 
IFX vs 92.31% with ADA; p=0.06), vitritis (78.95% with IFX vs 93.33% with ADA; p=0.04), 
retinal vasculitis (97% with IFX vs 95% with ADA; p=0.28), macular thickness (264.89±59.74 
with IFX vs 250.62±36.85 with ADA; p=0.15) and BCVA (0.67±0.34 with IFX vs 0.81±0.26 
with ADA; p=0.001). 
Drug retention rate at one year was better with ADA (84.95% with IFX vs 95.24% with ADA; 
p= 0.042). 
More rapid improvement of AC cells and vitritis was found in the IFX group (data not shown). 
An explanation for that may be that ADA loading dose was not given in our series of 
patients. However, ADA group achieved better results at one-year therapy, with statistical 
significance in BCVA and retention rate.  
In order to capture within patient correlation of repeated observations, we performed a mixed 
linear model using as covariates the factors that differ by a p-value on 0.1 in Table 1, as well 
as other plausible confounders. Once adjusted for the presence of basal choroiditis, use of 
oral corticosteroids or azathioprine before anti-TNF onset, BCVA differences at 12 months, 
were still favorable to ADA vs IFX therapy (p=0.007). The improvement in the values of 
BCVA in the different study periods is shown in Figure 1.  Adding to the model the presence 
of vitritis, age, sex, or duration of uveitis before anti-TNF onset, did not change these results. 
However, once adjusted for these variables, there were no significant differences between 
both arms of therapy concerning vitritis, retinitis or OCT measurements. 
At one year after the onset of anti-TNF therapy a reduction of the immunosuppression load 
score was also observed in both groups (from 9.07±4.14 in the IFX group and 8.01±5.24 in 
the ADA group [p=0.2] at baseline to 5.47±3.19 vs 4.79±3.52 [p=0.38], respectively at 1-year 











This article is protected by copyright. All rights reserved. 
mg (median [IQR]) at baseline to 5 [0-10] mg at 1 year in the IFX group, and from 20 [10-45] 
mg at baseline to 5 [2.5-10] mg at 1 year in the ADA group (p=0.9). 
 
Follow-up and side effects with ADA and IFX 
After a mean follow-up of 31.52±23.51 and 26.48±18.57 months with IFX and ADA 
respectively, ocular remission was achieved in 78 (76.47%) patients with IFX and in 65 
(87.84%) patients with ADA (p=0.33). However, the retention rate was statistically significant 
higher with ADA than with IFX (71.62% vs 44.12%; p <0.001). IFX was withdrawn in 57 
(55.33%) and ADA in 21 (28.37%) cases (p <0.01). With respect to this, IFX was 
discontinued because of remission in 20 patients. In the remaining 37 patients the reasons 
for IFX discontinuation were inefficacy (n=18), preference of another way of administration 
(n=9), toxicity/side effects (n=8), colon carcinoma (n=1), and pregnancy desire (n=1). In the 
case of ADA, it was discontinued because of remission in 6 patients whereas it was due to 
inefficacy (n=11) or toxicity/side effects (n=4) in the remaining 15 patients. 
Drug withdrawal due to severe side-effects or toxicity was observed in 8 patients with IFX 
and 4 with ADA. The 8 cases with IFX were due to infusional reactions in 4 cases, and 
tuberculosis, Mycobacterium avium pneumonia, severe oral ulcers, and palmoplantar skin 
reaction one each respectively. Four patients discontinued ADA therapy because of 
lymphoma, bacterial pneumonia, severe local reaction at the injection site, and bacteremia 
by Escherichia coli respectively. 
Data on remission, relapses, drug withdrawal and serious sides effects in both groups are 













This article is protected by copyright. All rights reserved. 
DISCUSSION 
In this multicenter study, we report on 177 cases of refractory BD-related uveitis treated with 
IFX (n=103) or ADA (n=74) as first biologic therapy. After one-year of follow up, patients 
treated with ADA achieved a better improvement of BCVA than those treated with IFX, as 
well as a greater retention rate, with a statistically significant difference between both 
groups. However, AC cells and vitritis improvement was observed more rapidly in the IFX 
group, what could be in part explained because of patients in ADA group did not receive the 
loading dose of 80 mg along with the next dose of 40 mg at one week as performed in the 
VISUAL trials since our study was carried out before these studies had been published. 
Several studies have demonstrated the presence of high levels of TNF-α -a potent and 
central ubiquitous proinflammatory cytokine- in serum and aqueous humor of patients with 
uveitis, including cases with BD-related uveitis [27-29]. Anti-TNF-α agents, IFX -a 
human/mouse chimeric monoclonal IgG1 antibody specific for TNF-α, administered 
intravenously- and ADA -a fully human monoclonal IgG1 antibody also specific for TNF-α, 
administered subcutaneously- have demonstrated efficacy in the treatment of BD uveitis 
refractory to conventional immunosuppressive therapy [12, 26, 30-38].  
In fact, ADA has recently been approved by the FDA and EMA for the use in non-infectious 
intermediate, posterior uveitis and panuveitis, included those due to BD. 
However, there are few studies comparing the efficacy of IFX and ADA to induce and 
maintain remission in these patients with refractory uveitis [11, 39, 40]. Moreover, these 
studies include generally patients with heterogeneous diseases, being patients with BD a 
minority of the total of the reported cases. 
The present study compared the efficacy of IFX versus ADA as first biologic drug in a large 
series of patients with BD uveitis refractory to conventional immunosuppressive drugs. In 
this regard, before the onset of the biologic therapy, all patients had received systemic high-
dose glucocorticoids and one or more conventional synthetic immunosuppressive drugs. 
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Although our study showed a rapid and maintained improvement of all ocular parameters 
with both anti-TNF-α drugs, significant differences were observed regarding BCVA 
improvement mediated by ADA therapy. It is possible that ADA versus IFX differences had 
been even more evident if we would have performed an intention-to-treat study instead of 
performing a per-protocol analysis, because a higher percentage of patients discontinued 
IFX due to inefficacy. 
Retention drug was also higher in the ADA group. This in part could be explained because of 
the route of administration since ADA is given subcutaneously in a rapid and comfortable 
way. Moreover, infusional reactions occur more frequently with IFX due to its chimeric nature 
and, probably, the occurrence of anti-drug antibodies may also be higher with IFX. 
Minor adverse effects such as mild infusion reaction to IFX and local reactions at the site of 
the injection of ADA were the most commonly observed side effects.  Severe complications 
leading to discontinuation of the biologic therapy were observed in 8 cases with IFX and 4 
with ADA. These agents had to be withdrawn due to inefficacy in 18 cases in the IFX group 
and 11 with ADA, comprising a low percentage of cases (17.5% and 14.9%, respectively). 
We realize that the study has several limitations due to its observational nature. Because of 
that, further randomized, controlled trials comparing head to head both anti-TNF-α agents 
are required. 
In conclusion, our study shows favorable results of ADA and IFX therapy at one year in BD-
refractory uveitis, with a statistically significant difference in favor of ADA in the improvement 
of BCVA as well as in the retention rate. 
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TABLE 1. Main baseline features and follow-up of a series of 177 patients with refractory 







Number of patients/affected eyes, (n/n) 103/185 74/131  
Age, mean (SD) years 40.4 (10.1) 38.7 (11.3) 0.29 
Sex, men/women, n/n 55/48 39/35 0.92 
HLA-B51 positive, (%) 69.4 68.9 0.74 
Duration of uveitis before anti-TNFα, median [IQR] months 36 [12-72] 24 [12-60] 0.69 
Ocular features at the time of anti TNF-α onset 
          AC cells, median [IQR] 
          Vitritis, median [IQR] 
          BCVA, mean (SD) 
          Macular thickness, mean (SD) 
          Presence of retinal vasculitis, n  






















Pattern of uveitis, (n/%) 
          Bilateral 
          Unilateral 
          Anterior 
          Posterior 
          Panuveitis 






















Treatment before anti TNF-α onset, (%) 
          Oral corticosteroids 
          Intravenous pulses of MP 
          CsA 
          AZA 
          MTX 






















Prednisone dose at anti TNF-α onset, mean (SD), mg/d 54.35 (15.84) 53.37 (17.52) 0.37 
Combined treatment, (%) 
          AZA 
          CsA 
          MTX 
          CFM 
          MMF 

















Follow-up on anti TNFα therapy, mean (SD), months 
          Remission, n (%) 
          Relapses, mean (SD) 
          Drug withdrawal, n (%) 
Remission, n (%) 
Inefficacy, n (%) 
Severe side-effects/toxicity, n (%) 
Others, n (%) 





























Abbreviations: ADA, adalimumab; AZA, azathioprine; CFM, cyclophosphamide; CsA, cyclosporine A; FK-506, 
tacrolimus; IFX, infliximab; IQR: interquartile range; MMF, mycophenolate mofetil; MTX, methotrexate; MP, 
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